Compound Reference Overview
| Field | Value |
|---|---|
| Name | Epitalon |
| Reference Code | EPIT |
| Category | Longevity |
| Example Strengths | 5 mg, 10 mg (varies by formulation) |
| Reference Range | 5 mg daily for 10–20 day cycles (reported in published human studies; investigational use) |
| Frequency | Once daily during defined 10–20 day cycles (literature reference) |
| Key Safety Warning | Theoretical concern exists regarding telomerase activation in individuals with active malignancy or recent cancer history. Contraindicated in pregnancy and breastfeeding. |
Mechanism of Action (Educational)
Epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) studied for its potential influence on cellular aging pathways. Published research suggests that Epitalon may stimulate telomerase activity through upregulation of hTERT expression, supporting telomere length maintenance in human somatic cells. Experimental data also indicate potential modulation of pineal gland function, with downstream effects on melatonin secretion and circadian rhythm regulation. Additional proposed mechanisms include antioxidant activity and
epigenetic signaling modulation associated with age-related cellular processes.
These mechanisms have been investigated primarily in experimental, longevity-focused, and preclinical research settings.
Indications (Literature)
- Telomere-associated cellular research
- Longevity and aging pathway investigations
- Circadian rhythm and melatonin-related studies
Administration (Literature)
| Parameter | Details |
|---|---|
| Route | Subcutaneous (most commonly reported in published human studies); intramuscular and intravenous routes described in research contexts |
| Frequency | Once daily during defined cycles |
| Injection Sites | Abdomen, thigh (standard subcutaneous sites) |
| Timing | Evening administration has been described in some literature due to potential circadian and pineal interactions |
Pharmacokinetics (Literature)
Comprehensive human pharmacokinetic data remain limited. Available literature describes cellular and molecular effects observed over days to weeks following administration in investigational settings.
Detailed absorption, distribution, metabolism, and elimination parameters have not been fully characterized in large-scale clinical trials. Long-term pharmacodynamic outcomes continue to be evaluated in experimental research contexts.
Titration Schedule (Literature)
No formal titration schedule has been established in large-scale randomized clinical trials. Published literature generally describes fixed daily amounts administered for defined periods, typically ranging from 10 to 20 consecutive days per cycle.
Reconstitution & Concentration (Mathematical Standardization Model)
For educational standardization purposes, concentration may be normalized so that 0.10 mL (10 insulin units) = 0.5 mg (500 mcg). This supports clean unit-to-milligram conversion during investigational daily cycles.
| Parameter | Value |
|---|---|
| Target Concentration | 5 mg/mL (5000 mcg/mL) |
| Unit Conversion | 0.10 mL (10 units) = 0.5 mg |
| Example (10 mg vial) | Reconstitute with 2.0 mL bacteriostatic water → 5 mg/mL |
| Stability | Up to 28 days refrigerated (varies by formulation and compounding standards) |
Conversion Reference
- 10 units = 0.5 mg
- 20 units = 1.0 mg
- 40 units = 2.0 mg
- 60 units = 3.0 mg
- 80 units = 4.0 mg
- 100 units = 5.0 mg
This section is provided strictly for arithmetic illustration and does not constitute dosing guidance. Research or compounded formulations may differ in preparation and handling requirements.
Safety & Contraindications (Summary)
Contraindications
- Active malignancy or recent cancer history (theoretical concern related to telomerase activation)
- Pregnancy or breastfeeding
- Known hypersensitivity to peptide components
Adverse Events
- Injection site reactions
- Headache
- Drowsiness
Serious Adverse Events
- No major serious adverse events reported in limited human studies; long-term safety data remain limited
Drug Interactions
- No well-documented drug interactions reported in available literature
Monitoring (Literature)
- Sleep quality and circadian rhythm patterns
- General wellbeing
- Investigational telomere length assessment in research settings
Mathematical Calculation Tool
The calculator below allows mathematical concentration and volume calculations using variable vial strengths and reconstitution volumes. This tool is provided strictly for arithmetic reference.
Peptide Reconstitution Calculator
For Educational & Professional Reference Only
Disclaimer
This content is provided strictly as a pharmacologic and mathematical reference for educational and professional purposes. It does not constitute medical advice, prescribing guidance, diagnosis, or treatment recommendations. All clinical decisions must be made by a licensed healthcare professional in accordance with applicable regulations.
Reference Sources
1. Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells.
Bull Exp Biol Med. 2003; PMID: 12937682.
2. Khavinson VK, Izmaylov DM, Obukhova LK. Effect of epitalon on lifespan increase in Drosophila melanogaster.
Mech Ageing Dev. 2000; PMID: 11087911.
3. Araj SK, Brzezik J, et al. Overview of Epitalon – Highly Bioactive Pineal Tetrapeptide.
Int J Mol Sci. 2025; PMID: 40141333.
4. Al-Dulaimi S, Thomas R, et al. Epitalon increases telomere length in human cell lines through telomerase upregulation.
Biogerontology. 2025; PMID: 40908429.
5. Khavinson V, Goncharova N, Lapin B. Synthetic tetrapeptide epitalon restores disturbed neuroendocrine regulation in senescent monkeys.
Neuro Endocrinol Lett. 2001; PMID: 11524632.